Key facts
- Terrestrial Bio’s last known valuation is $96.1M (Jul 2023).
- It has raised $136.2M across 5 recorded rounds; the latest was Later Stage VC ($57.3M) in Mar 2026.
- Notable investors include US National Science Foundation, RA Capital Management, Harvard Innovation Launch Lab, Gates Foundation, The Engine — 25 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Terrestrial Bio
Funding rounds
5 roundsAbout Terrestrial Bio
Developer of novel therapies designed to help in oncology care and infectious diseases. The company's microarray patch (MAP) and applicator platform consists of a patch resembling an adhesive bandage, which is applied with a preloaded applicator and removed after a few minutes, enabling healthcare practitioners to improve patient outcomes with decreased treatment burdens.
- Industry
- Drug Delivery
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2011
- Employees
- 42
- Website
- terrestrialbio.com/
- Ownership
- Privately Held (backing)
Terrestrial Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Terrestrial Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Terrestrial Bio in its N-PORT filings yet. We sweep new filings monthly.